When was Cala Health founded?

Cala Health was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Cala Health located?

Cala Health is headquartered in Stanford, United States.

Who is the current CEO of Cala Health?

Deanna Harshbarger of Cala Health. They have also founded 1 company.

How many employees does Cala Health have?

As of Aug 31, 2026, the latest employee count at Cala Health is 127.

Is Cala Health a funded company?

Cala Health is a funded company, having raised a total of $257M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2013.

When was the latest funding round of Cala Health?

Cala Health's latest funding was a $***** Conventional Debt round on Apr 21, 2026, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.05B in funding in 2026 to date.

Where does Cala Health rank among its competitors?

Cala Health ranks 2nd amongst 103 active competitors, of which 29 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Cala Health, which secured $50M in Apr, 2026.

Who are the top competitors of Cala Health?

Cala Health's top competitors include Ceribell, Kernel and Encora Therapeutics. Among them, Cala Health secured the most recent funding round in April, 2026.

Cala Health - 2026 Company Profile, Team, Funding & Competitors

Cala Health is a series D company based in Stanford (United States), founded in 2013 by Deanna Harshbarger. It operates as a Developer of a wearable non-invasive neuromodulation device. Cala Health has raised $257M in funding from investors like Lux Capital, Baird Capital and Novartis. The company has 103 active competitors, including 29 funded and 5 that have exited. Its top competitors include companies like Ceribell, Kernel and Encora Therapeutics.

Company Details

Developer of a wearable non-invasive neuromodulation device. The company has developed a neuromodulation device that aims to provide relief of hand tremors in adults with essential tremors. It combines a watch-like device with an implantable sensor that externally stimulates peripheral nerves to reduce the same. The company has also developed a portable medical device with sensors to monitor the physical movement of a patient wearing or carrying the device.

Website: calahealth.com
Social

Key Metrics

Founded Year

2013

Location

Stanford, United States

Stage

Series D

Total Funding

$257M in 9 rounds

Latest Funding Round

Conventional Debt, Apr 21, 2026, $*****

Investors

Lux Capital & 30 more

Ranked

2^nd among 103 active competitors

Employee Count

127 as on Aug 31, 2026

Similar Companies

Ceribell & 122 more

View Cala Health's full profile

Cala Health is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cala Health, Inc. CIN: 0018y000008XrQpAAK , United States, Active	Feb 21, 2023	-	-	-
Cala Health, Inc. CIN: 463048688 , United States, Active	Jun 23, 2013	-	70 (As on Dec 31, 2024)	-

Cala Health has raised a total funding of $257M over 9 rounds. Its first funding round was on 2013. Its latest funding round was a Conventional Debt round on Apr 21, 2026 for $*****. 1 investor participated in its latest round. Cala Health has 31 institutional investors.

Here is the list of recent funding rounds of Cala Health:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 21, 2026	9460770	Conventional Debt	5938102	6952904	4526705	7774030
Oct 20, 2025	7688865	Series D	9635704	2356500	8054065	Niterra
Dec 09, 2024	6701305	Series D	4950409	7022885	Vertex Growth & 1 more	Action Potential Venture Capital & 10 more

Access funding benchmarks and valuations. Sign up today!

View details of Cala Health's funding rounds and investors

The founders of Cala Health is Deanna Harshbarger. Deanna Harshbarger is the CEO of Cala Health.

Here are the details of Cala Health's key team members:

Deanna Harshbarger: CEO of Cala Health.

View details of Cala Health's Founder profiles and Board Members

Cala Health's employee count trend

Cala Health has 127 employees as of Aug 26. Here is Cala Health's employee count trend over the years:

Uncover Cala Health's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cala Health include Ceribell, Kernel and Encora Therapeutics. Here is the list of Top 10 competitors of Cala Health, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ceribell 2014, Mountain View (United States), Public	EEG system for the diagnosis of seizures	$188M	The Rise Fund, Longitude Capital & 11 others	69/100
2nd	Cala Health 2013, Stanford (United States), Series D	Developer of a wearable non-invasive neuromodulation device	$257M	AME Cloud Ventures, Innovatus Capital Partners ... & 29 others	63/100
3rd	Kernel 2016, Los Angeles (United States), Series C	Developer of multimodal brain measurement technology for neuromedicine	$158M	General Catalyst, Eldridge Industries & 3 others	57/100
4th	Encora Therapeutics 2018, Cambridge (United States), Seed	Developer of smart devices for the treatment of neurological movement disorders	$1.5M	Innospark Ventures, SDX Energy & 2 others	53/100
5th	Sense Neuro Diagnostics 2013, Cincinnati (United States), Seed	Non-invasive brain activity monitoring device	$4.64M	Queen City Angels, Defense.gov & 3 others	51/100
6th	NeuroEM 2013, Tampa (United States), Series A	Developer of medical device a non-invasive treatment for cognitive decline	$9M	Bluelake, New York Angels & 1 others	50/100
7th	Mendi 2017, Stockholm (Sweden), Seed	Provider of wearable brain training devices	$8.21M	First Venture, EIC Fund & 8 others	50/100
8th	Steadiwear 2015, Toronto (Canada), Seed	Designer & manufacturer of healthcare gloves	$1.29M	3W Partners, MassChallenge & 9 others	49/100
9th	Aleva Neuro 2008, Lausanne (Switzerland), Series E	Develops implantable deep brain stimulation systems that enables therapies for neurological diseases	$57M	CIP Merchant Capital, Venture Kick & 11 others	47/100
10th	InBrain Pharma 2018, Paris (France), Seed	Developer of therapeutic solutions for the treatment of neurodegenerative diseases	$3.15M	Finovam Gestion, Nord France Amorquage	46/100